These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 8232355)

  • 1. Relief of akinesia by apomorphine and cerebral metabolic changes in Parkinson's disease.
    Broussolle E; Cinotti L; Pollak P; Landais P; Le Bars D; Galy G; Lavenne F; Khalfallah Y; Chazot G; Mauguière F
    Mov Disord; 1993 Oct; 8(4):459-62. PubMed ID: 8232355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of local cerebral glucose utilization determined in Parkinson's disease by the [18F]fluorodeoxyglucose method.
    Kuhl DE; Metter EJ; Riege WH
    Ann Neurol; 1984 May; 15(5):419-24. PubMed ID: 6610384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on apomorphine for the rapid treatment of hypomobility ("off") episodes in Parkinson's disease.
    Obering CD; Chen JJ; Swope DM
    Pharmacotherapy; 2006 Jun; 26(6):840-52. PubMed ID: 16716137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine.
    Jenkins IH; Fernandez W; Playford ED; Lees AJ; Frackowiak RS; Passingham RE; Brooks DJ
    Ann Neurol; 1992 Dec; 32(6):749-57. PubMed ID: 1471865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.
    Bravi D; Mouradian MM; Roberts JW; Davis TL; Sohn YH; Chase TN
    Ann Neurol; 1994 Jul; 36(1):27-31. PubMed ID: 8024257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ; Obering C
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired activity of the supplementary motor area in akinetic patients with Parkinson's disease. Improvement by the dopamine agonist apomorphine.
    Rascol OJ; Sabatini U; Chollet F; Montastruc JL; Marc-Vergnes JP; Rascol A
    Adv Neurol; 1993; 60():419-21. PubMed ID: 8420165
    [No Abstract]   [Full Text] [Related]  

  • 8. Increased cortical inhibition induced by apomorphine in patients with Parkinson's disease.
    Manfredi L; Garavaglia P; Beretta S; Pellegrini G
    Neurophysiol Clin; 1998 Feb; 28(1):31-8. PubMed ID: 9562997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apomorphine in patients with Parkinson's disease.
    Muguet D; Broussolle E; Chazot G
    Biomed Pharmacother; 1995; 49(4):197-209. PubMed ID: 7669939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain energy metabolism and dopaminergic function in Huntington's disease measured in vivo using positron emission tomography.
    Leenders KL; Frackowiak RS; Quinn N; Marsden CD
    Mov Disord; 1986; 1(1):69-77. PubMed ID: 2973559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of bilateral subthalamic nucleus stimulation on resting-state cerebral glucose metabolism in advanced Parkinson's disease.
    Zhao YB; Sun BM; Li DY; Wang QS
    Chin Med J (Engl); 2004 Sep; 117(9):1304-8. PubMed ID: 15377418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of subcutaneous apomorphine on tremor in idiopathic Parkinson's disease.
    Hellmann MA; Sabach T; Melamed E; Djaldetti R
    Biomed Pharmacother; 2008; 62(4):250-2. PubMed ID: 17967525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apomorphine continuous stimulation in Parkinson's disease: receptor desensitization as a possible mechanism of reduced motor response.
    Maggio R; Barbier P; Corsini GU
    J Neural Transm Suppl; 1995; 45():133-6. PubMed ID: 8748618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease.
    Tison F; Wiart L; Guatterie M; Fouillet N; Lozano V; Henry P; Barat M
    Mov Disord; 1996 Nov; 11(6):729-32. PubMed ID: 8914103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perfusion-weighted dynamic susceptibility (DSC) MRI: basal ganglia hemodynamic changes after apomorphine in Parkinson's disease.
    Brusa L; Bassi A; Pierantozzi M; Gaudiello S Frasca F; Floris R; Stanzione P
    Neurol Sci; 2002 Sep; 23 Suppl 2():S61-2. PubMed ID: 12548344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute akinesia in Parkinson disease.
    Onofrj M; Thomas A
    Neurology; 2005 Apr; 64(7):1162-9. PubMed ID: 15824341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Apomorphine for treatment of "off-periods" in Parkinson's disease].
    Zoldan J; Merims D; Kuritzky A; Ziv I; Melamed E
    Harefuah; 1999 Nov; 137(10):444-6, 512, 511. PubMed ID: 10959339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
    Katzenschlager R; Hughes A; Evans A; Manson AJ; Hoffman M; Swinn L; Watt H; Bhatia K; Quinn N; Lees AJ
    Mov Disord; 2005 Feb; 20(2):151-7. PubMed ID: 15390035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apomorphine increases blood glucose concentrations in Parkinson's disease.
    Tison F; Fouillet N; Henry P
    Clin Neuropharmacol; 1994 Feb; 17(1):92-5. PubMed ID: 8149364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modifications of local cerebral metabolic rates for glucose and motor behavior in rats with unilateral lesion of the subthalamic nucleus.
    Blandini F; Conti G; Martignoni E; Colangelo V; Nappi G; Di Grezia R; Orzi F
    J Cereb Blood Flow Metab; 1999 Feb; 19(2):149-54. PubMed ID: 10027770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.